ES2982904T3 - Anticuerpos que comprenden dominios constantes quiméricos - Google Patents
Anticuerpos que comprenden dominios constantes quiméricos Download PDFInfo
- Publication number
- ES2982904T3 ES2982904T3 ES18179622T ES18179622T ES2982904T3 ES 2982904 T3 ES2982904 T3 ES 2982904T3 ES 18179622 T ES18179622 T ES 18179622T ES 18179622 T ES18179622 T ES 18179622T ES 2982904 T3 ES2982904 T3 ES 2982904T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antibody
- amino acid
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 84
- 229920001184 polypeptide Polymers 0.000 claims abstract description 81
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 230000014509 gene expression Effects 0.000 claims abstract description 42
- 108091006020 Fc-tagged proteins Proteins 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims description 179
- 230000027455 binding Effects 0.000 claims description 146
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 127
- 150000007523 nucleic acids Chemical class 0.000 claims description 65
- 102000039446 nucleic acids Human genes 0.000 claims description 60
- 108020004707 nucleic acids Proteins 0.000 claims description 60
- 102000005962 receptors Human genes 0.000 claims description 48
- 108020003175 receptors Proteins 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 40
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 16
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 16
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 12
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 101150061166 tetR gene Proteins 0.000 claims description 5
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 101150015970 tetM gene Proteins 0.000 claims description 4
- 101100394813 Bacillus subtilis (strain 168) hprT gene Proteins 0.000 claims description 3
- 101100030550 Nocardia iowensis npt gene Proteins 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 101150047832 hpt gene Proteins 0.000 claims description 3
- 229930189065 blasticidin Natural products 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 70
- 239000012636 effector Substances 0.000 abstract description 46
- 230000006870 function Effects 0.000 abstract description 34
- 102000025171 antigen binding proteins Human genes 0.000 abstract description 20
- 108091000831 antigen binding proteins Proteins 0.000 abstract description 20
- 102000009109 Fc receptors Human genes 0.000 abstract description 19
- 108010087819 Fc receptors Proteins 0.000 abstract description 19
- 230000002829 reductive effect Effects 0.000 abstract description 19
- 230000001413 cellular effect Effects 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 description 120
- 108091007433 antigens Proteins 0.000 description 120
- 102000036639 antigens Human genes 0.000 description 120
- 239000002773 nucleotide Substances 0.000 description 54
- 125000003729 nucleotide group Chemical group 0.000 description 54
- 239000012634 fragment Substances 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 49
- 150000001413 amino acids Chemical class 0.000 description 48
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 40
- 230000003013 cytotoxicity Effects 0.000 description 39
- 231100000135 cytotoxicity Toxicity 0.000 description 39
- 108020001507 fusion proteins Proteins 0.000 description 39
- 102000037865 fusion proteins Human genes 0.000 description 39
- 230000000694 effects Effects 0.000 description 35
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 230000001472 cytotoxic effect Effects 0.000 description 23
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- 102000018358 immunoglobulin Human genes 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 108010091086 Recombinases Proteins 0.000 description 8
- 102000018120 Recombinases Human genes 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 7
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 7
- 230000022534 cell killing Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229960002378 oftasceine Drugs 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 6
- 108010034634 Repressor Proteins Proteins 0.000 description 6
- 102000009661 Repressor Proteins Human genes 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 101150024821 tetO gene Proteins 0.000 description 6
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 5
- 102100025976 Adenosine deaminase 2 Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 5
- 101000720051 Homo sapiens Adenosine deaminase 2 Proteins 0.000 description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241000282553 Macaca Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000009830 antibody antigen interaction Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 102100037935 Polyubiquitin-C Human genes 0.000 description 4
- 108010056354 Ubiquitin C Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000000611 regression analysis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010057248 Cell death Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 238000012450 HuMAb Mouse Methods 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101150025323 SCLT1 gene Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- -1 bSa Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010045123 Blasticidin-S deaminase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 101150040913 DUT gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108700019828 Hinge Exons Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000913079 Homo sapiens IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 1
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 description 1
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917821 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-c Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 1
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 description 1
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150092610 PKH2 gene Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 101150073130 ampR gene Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000053391 human F Human genes 0.000 description 1
- 108700031895 human F Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- 238000012349 terminal deoxynucleotidyl transferase dUTP nick-end labeling Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759578P | 2013-02-01 | 2013-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2982904T3 true ES2982904T3 (es) | 2024-10-18 |
Family
ID=50156909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18179622T Active ES2982904T3 (es) | 2013-02-01 | 2014-01-31 | Anticuerpos que comprenden dominios constantes quiméricos |
| ES14706169.1T Active ES2687866T3 (es) | 2013-02-01 | 2014-01-31 | Anticuerpos que comprenden dominios constantes quiméricos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14706169.1T Active ES2687866T3 (es) | 2013-02-01 | 2014-01-31 | Anticuerpos que comprenden dominios constantes quiméricos |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9359437B2 (enExample) |
| EP (3) | EP4417624A3 (enExample) |
| JP (3) | JP6422445B2 (enExample) |
| KR (1) | KR102229732B1 (enExample) |
| CN (1) | CN104955844B (enExample) |
| AR (1) | AR095115A1 (enExample) |
| AU (2) | AU2014212148B2 (enExample) |
| CA (1) | CA2899457C (enExample) |
| DK (2) | DK3406634T3 (enExample) |
| EA (1) | EA032960B1 (enExample) |
| ES (2) | ES2982904T3 (enExample) |
| FI (1) | FI3406634T3 (enExample) |
| HU (2) | HUE040415T2 (enExample) |
| IL (1) | IL239688B (enExample) |
| MX (2) | MX360746B (enExample) |
| MY (2) | MY176294A (enExample) |
| NZ (1) | NZ710598A (enExample) |
| PL (2) | PL3406634T3 (enExample) |
| SG (2) | SG11201505072RA (enExample) |
| TW (2) | TWI635098B (enExample) |
| WO (1) | WO2014121087A1 (enExample) |
| ZA (1) | ZA201504697B (enExample) |
Families Citing this family (219)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3250882A1 (en) | 2010-08-02 | 2025-11-29 | Regeneron Pharamaceuticals, Inc. | Mice that Make Binding Proteins Comprising VL Domains |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| EA201691027A1 (ru) | 2013-11-20 | 2016-12-30 | Ридженерон Фармасьютикалз, Инк. | Модуляторы aplnr и их применение |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| JP2017533695A (ja) | 2014-09-16 | 2017-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗グルカゴン抗体およびその使用 |
| SMT202000438T1 (it) | 2014-11-17 | 2020-09-10 | Regeneron Pharma | Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20 |
| CA2967823A1 (en) | 2014-11-24 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
| EP3227436B1 (en) | 2014-12-05 | 2024-11-13 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| KR102701479B1 (ko) | 2014-12-05 | 2024-09-03 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 |
| EP3227432B1 (en) | 2014-12-05 | 2023-10-11 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
| TW201713361A (zh) | 2015-04-29 | 2017-04-16 | Regeneron Pharma | 進行性骨化性纖維發育不良之治療 |
| EA039429B1 (ru) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Способы лечения опухолей с применением биспецифического антитела cd3xcd20 |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| KR101712638B1 (ko) * | 2015-08-19 | 2017-03-07 | 한국과학기술연구원 | Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| SG10202005268WA (en) | 2015-12-04 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| IL313952A (en) | 2015-12-22 | 2024-08-01 | Regeneron Pharma | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| CA3015371A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| IL321475A (en) * | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| JP2019528082A (ja) * | 2016-06-08 | 2019-10-10 | シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| EP4374922A3 (en) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| CN106191072A (zh) * | 2016-08-04 | 2016-12-07 | 沈沭彤 | 重组人源嵌合GcFc基因片段及融合蛋白 |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| EP4613772A3 (en) | 2016-11-08 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
| MY200034A (en) | 2017-02-10 | 2023-12-05 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| CN114989305A (zh) * | 2017-03-31 | 2022-09-02 | 北京智仁美博生物科技有限公司 | 新型双特异性抗体及其用途 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7161494B2 (ja) | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| MA50546A (fr) | 2017-06-07 | 2020-09-16 | Regeneron Pharma | Compositions et méthodes pour l'internalisation d'enzymes |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| CA3066779A1 (en) | 2017-06-28 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
| TWI865430B (zh) | 2017-07-24 | 2024-12-11 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
| BR112020001360A2 (pt) | 2017-07-24 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto. |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR20200058525A (ko) | 2017-09-29 | 2020-05-27 | 리제너론 파아마슈티컬스, 인크. | 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도 |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| CN111542540A (zh) | 2017-12-18 | 2020-08-14 | 瑞泽恩制药公司 | 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法 |
| CN109971720B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| EP3514171A1 (en) * | 2018-01-18 | 2019-07-24 | Molecular Cloning Laboratories (MCLAB) LLC | Long-acting therapeutic fusion proteins |
| JP7372925B2 (ja) | 2018-01-26 | 2023-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インフルエンザヘマグルチニンに対するヒト抗体 |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| LT3772927T (lt) | 2018-03-24 | 2025-02-10 | Regeneron Pharmaceuticals, Inc. | Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas |
| HRP20250986T1 (hr) | 2018-04-06 | 2025-10-24 | Regeneron Pharmaceuticals, Inc. | Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| AU2019269685B2 (en) | 2018-05-17 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
| MA52966A (fr) | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| TWI890661B (zh) | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| LT3844189T (lt) | 2018-08-31 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą |
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| CN112867732A (zh) | 2018-11-21 | 2021-05-28 | 瑞泽恩制药公司 | 抗葡萄球菌抗体和其用途 |
| MA54545A (fr) | 2018-12-21 | 2021-10-27 | Regeneron Pharma | Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci |
| EP3917962A1 (en) | 2019-02-01 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| WO2020167919A1 (en) | 2019-02-12 | 2020-08-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| JP2022521751A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| SG11202109056TA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2599227B (en) | 2019-02-21 | 2024-05-01 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
| JP7659501B2 (ja) | 2019-03-22 | 2025-04-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ＥＧＦＲｘＣＤ２８多特異性抗体 |
| CN113711037A (zh) * | 2019-04-18 | 2021-11-26 | 基因泰克公司 | 抗体效力测定 |
| CA3137284A1 (en) | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| AU2020292283A1 (en) | 2019-06-11 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
| US20200399372A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
| CN113993547B (zh) | 2019-06-21 | 2024-04-26 | 瑞泽恩制药公司 | 结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途 |
| CN114585651A (zh) | 2019-08-08 | 2022-06-03 | 再生元制药公司 | 新型抗原结合分子形式 |
| BR112022002012A2 (pt) | 2019-08-15 | 2022-06-07 | Regeneron Pharma | Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| BR112022007923A2 (pt) | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
| JP7785669B2 (ja) | 2019-11-05 | 2025-12-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｎ末端ｓｃＦｖ多重特異性結合分子 |
| CA3160352A1 (en) | 2019-12-06 | 2021-06-10 | Israel Lowy | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| TW202136317A (zh) | 2019-12-20 | 2021-10-01 | 美商再生元醫藥公司 | 新穎之ｉｌ２促效劑及其使用方法（二） |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021142191A1 (en) | 2020-01-08 | 2021-07-15 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| MX2022009769A (es) | 2020-02-11 | 2022-11-09 | Regeneron Pharma | Anticuerpos anti-acvr1 y usos de los mismos. |
| CN111411079B (zh) * | 2020-03-27 | 2025-12-12 | 北京时合生物科技有限公司 | 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用 |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| AU2021270563A1 (en) | 2020-05-12 | 2022-12-15 | Regeneron Pharmaceuticals, Inc. | Novel IL10 agonists and methods of use thereof |
| US11999777B2 (en) | 2020-06-03 | 2024-06-04 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| EP4204458A4 (en) | 2020-08-26 | 2024-10-09 | Marengo Therapeutics, Inc. | METHODS FOR DETECTION OF TRBC1 OR TRBC2 |
| JP2023542080A (ja) | 2020-08-26 | 2023-10-05 | マレンゴ・セラピューティクス，インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
| AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
| WO2022060915A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| AU2021343444A1 (en) | 2020-09-15 | 2023-04-20 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
| JP2023543152A (ja) | 2020-09-18 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| US20230374160A1 (en) | 2020-10-02 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| JP7767411B2 (ja) | 2020-10-22 | 2025-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｆｇｆｒ２抗体及びその使用方法 |
| US20230391864A1 (en) | 2020-10-28 | 2023-12-07 | Regenxbio, Inc. | Vectorized anti-tnf-alpha antibodies for ocular indications |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| EP4236974A2 (en) | 2020-10-29 | 2023-09-06 | RegenxBio Inc. | Vectorized factor xii antibodies and administration thereof |
| CN116457373A (zh) | 2020-10-29 | 2023-07-18 | 再生生物股份有限公司 | 用于眼部适应症的载体化TNF-α拮抗剂 |
| WO2022133239A1 (en) | 2020-12-18 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to npr1 agonists |
| TW202241943A (zh) | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau特異性抗體基因療法組合物、方法及其用途 |
| WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| US20250099579A1 (en) | 2021-04-08 | 2025-03-27 | Marengo Therapeutics, Inc. | Multispecific molecules binding to tcr and uses thereof |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| EP4334353A1 (en) | 2021-05-04 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| AU2022274888A1 (en) | 2021-05-11 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| US20250066441A1 (en) | 2021-07-19 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| AU2022331241A1 (en) | 2021-08-16 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| AU2022383847A1 (en) | 2021-11-11 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| US20230235089A1 (en) | 2021-11-24 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies |
| CA3239802A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| EP4460520A1 (en) | 2022-01-07 | 2024-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
| IL315254A (en) | 2022-03-03 | 2024-10-01 | Univ Yale | Human 3E10 antibodies, variants and antigen-binding fragments thereof |
| WO2023177772A1 (en) | 2022-03-17 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
| EP4518972A2 (en) | 2022-05-03 | 2025-03-12 | RegenxBio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| CA3252786A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | PROPROTEINS OF MULTISPECIFIC BONDING MOLECULES AND THEIR USES |
| IL316751A (en) | 2022-05-16 | 2025-01-01 | Regeneron Pharma | Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies |
| EP4525993A1 (en) | 2022-05-18 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| KR20250030976A (ko) | 2022-05-27 | 2025-03-05 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-2 프로프로테인 및 이의 용도 |
| US20230391844A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| CA3258639A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules to modulate T lymphocyte activity, and their uses |
| CA3263494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| IL318636A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Viral particles retargeted to transferrin receptor 1 |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| TW202413434A (zh) | 2022-08-02 | 2024-04-01 | 美商再生元醫藥公司 | 以組合抗PD-1抗體之雙特異性抗PSMA x 抗CD28抗體治療轉移性去勢抗性前列腺癌之方法 |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| CN120051483A (zh) | 2022-08-18 | 2025-05-27 | 再生元制药公司 | 干扰素前蛋白及其用途 |
| JP2025533075A (ja) | 2022-10-03 | 2025-10-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ＥＧＦＲｘＣＤ２８抗体単独又は抗ＰＤ－１抗体との併用による癌治療方法 |
| EP4601748A1 (en) | 2022-10-10 | 2025-08-20 | Regeneron Pharmaceuticals, Inc. | Methods for reducing alloantibody levels in subjects in need of solid organ transplantation |
| WO2024092038A2 (en) | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
| EP4608865A1 (en) | 2022-10-27 | 2025-09-03 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
| US20240182561A1 (en) | 2022-11-04 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| KR20250120451A (ko) | 2022-11-14 | 2025-08-08 | 리제너론 파마슈티칼스 인코포레이티드 | 항-fgfr3 항체 및 항원 결합 단편 및 이의 사용 방법 |
| WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| EP4634220A2 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
| WO2024137731A2 (en) | 2022-12-21 | 2024-06-27 | Genzyme Corporation | Anti‑pd‑1×4‑1bb binding proteins |
| US20240252601A1 (en) | 2022-12-23 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
| WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| AU2024207469A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| KR20250150011A (ko) | 2023-02-13 | 2025-10-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료 |
| AR131856A1 (es) | 2023-02-16 | 2025-05-07 | Sanofi Sa | Proteínas de unión a cd40 |
| EP4665385A2 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| WO2024182540A2 (en) | 2023-02-28 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| IL322940A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multivalent anti-spike protein binding molecules and their uses |
| KR20250157402A (ko) | 2023-02-28 | 2025-11-04 | 리제너론 파아마슈티컬스, 인크. | 다가 항스파이크 단백질 결합 분자 및 그 용도 |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| WO2024233926A1 (en) | 2023-05-10 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
| US20250011449A1 (en) | 2023-06-11 | 2025-01-09 | Regeneron Pharmaceuticals, Inc. | Circularized antibody molecules |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| WO2025014913A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| US20250043017A1 (en) | 2023-07-10 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025019789A1 (en) | 2023-07-19 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| TW202513801A (zh) | 2023-07-28 | 2025-04-01 | 美商雷傑納榮製藥公司 | 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入 |
| TW202519551A (zh) | 2023-07-28 | 2025-05-16 | 美商雷傑納榮製藥公司 | 用於治療酸性神經髓磷脂酶缺乏症之抗ＴｆＲ：酸性神經髓磷脂酶 |
| WO2025030041A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies |
| WO2025030044A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies |
| WO2025049591A1 (en) | 2023-08-28 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Anti-cxcr4 antibodies and uses thereof |
| WO2025080540A1 (en) | 2023-10-09 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine |
| WO2025101851A1 (en) | 2023-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| WO2025117869A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific anti-muc16 x anti-cd28 antibodies in combination with anti-pd-1 antibodies or bispecific anti-muc16 x anti-cd3 antibodies |
| WO2025122614A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025128652A1 (en) | 2023-12-12 | 2025-06-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025171124A1 (en) | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| US20250297006A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025240287A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| WO2025245494A1 (en) | 2024-05-24 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il12 receptor agonists |
| WO2025255452A2 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses thereof |
| US20250376524A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| US20250376667A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
| WO2025259718A2 (en) | 2024-06-11 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5824543A (en) | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| AU2002245272B2 (en) | 2001-01-16 | 2006-06-29 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| JP4524074B2 (ja) | 2001-03-09 | 2010-08-11 | アーナソン， バリー ジー． | 低親和性Ｆｃγレセプターを標的化する重合体の免疫グロブリン融合タンパク質 |
| WO2003026490A2 (en) | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20070041972A1 (en) | 2003-05-30 | 2007-02-22 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| US8784821B1 (en) | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
| US20050163782A1 (en) | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| PL1737891T3 (pl) * | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| EP1753783B1 (en) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
| TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| CA2625619A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| KR20140091765A (ko) | 2006-01-12 | 2014-07-22 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도 |
| CA3022097C (en) | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
| DK2769992T3 (da) | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Humane antistoffer med høj affinitet for human IL-4-receptor |
| CA2681974C (en) | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| EP3173484B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| CA2689895A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Non-glycosylated recombinant monovalent antibodies |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| US20110313134A1 (en) | 2008-11-06 | 2011-12-22 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| RS53980B1 (sr) | 2008-11-07 | 2015-10-30 | Amgen Research (Munich) Gmbh | Tretiranje akutne limfoblastne leukemije kod dece |
| AR074438A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| EP2481752B1 (en) | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| ES2609043T3 (es) | 2009-11-30 | 2017-04-18 | Janssen Biotech, Inc. | Anticuerpos mutantes Fc con funciones de efecto abladas |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| BR112012024489A2 (pt) | 2010-03-29 | 2016-05-31 | Zymeworks Inc | anticorpos com função efetora suprimida ou aumentada |
| WO2011137362A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Antibodies having reduced immunogenicity in a human |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| EP2616489B1 (en) | 2010-09-16 | 2016-12-14 | Baliopharm AG | Anti-hutnfr1 antibody |
| MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
| DK2654780T3 (en) | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| HK1203528A1 (zh) | 2012-01-27 | 2015-10-30 | Gliknik Inc. | 包含igg2鉸鏈結構域的融合蛋白 |
| EA036225B1 (ru) | 2012-03-14 | 2020-10-15 | Ридженерон Фармасьютикалз, Инк. | Мультиспецифические антигенсвязывающие молекулы и их применения |
| SG11201407644UA (en) | 2012-06-05 | 2014-12-30 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
| AU2013289883B2 (en) | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| LT2900694T (lt) | 2012-09-27 | 2018-11-12 | Merus N.V. | Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| AU2014287011A1 (en) | 2013-07-12 | 2016-02-25 | Zymeworks Inc. | Bispecific CD3 and CD19 antigen binding constructs |
| EP3736292B1 (en) | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3083696B1 (en) | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| TWI890661B (zh) | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
-
2014
- 2014-01-29 TW TW103103362A patent/TWI635098B/zh active
- 2014-01-29 TW TW107120676A patent/TWI682941B/zh active
- 2014-01-31 DK DK18179622.8T patent/DK3406634T3/da active
- 2014-01-31 PL PL18179622.8T patent/PL3406634T3/pl unknown
- 2014-01-31 MY MYPI2015001658A patent/MY176294A/en unknown
- 2014-01-31 ES ES18179622T patent/ES2982904T3/es active Active
- 2014-01-31 EP EP24172994.6A patent/EP4417624A3/en active Pending
- 2014-01-31 MY MYPI2018702010A patent/MY189467A/en unknown
- 2014-01-31 HU HUE14706169A patent/HUE040415T2/hu unknown
- 2014-01-31 DK DK14706169.1T patent/DK2951207T3/en active
- 2014-01-31 US US14/170,166 patent/US9359437B2/en active Active
- 2014-01-31 AU AU2014212148A patent/AU2014212148B2/en active Active
- 2014-01-31 NZ NZ710598A patent/NZ710598A/en unknown
- 2014-01-31 CA CA2899457A patent/CA2899457C/en active Active
- 2014-01-31 SG SG11201505072RA patent/SG11201505072RA/en unknown
- 2014-01-31 AR ARP140100334A patent/AR095115A1/es active IP Right Grant
- 2014-01-31 EA EA201591407A patent/EA032960B1/ru not_active IP Right Cessation
- 2014-01-31 CN CN201480006932.5A patent/CN104955844B/zh active Active
- 2014-01-31 JP JP2015556172A patent/JP6422445B2/ja active Active
- 2014-01-31 ES ES14706169.1T patent/ES2687866T3/es active Active
- 2014-01-31 EP EP14706169.1A patent/EP2951207B1/en active Active
- 2014-01-31 EP EP18179622.8A patent/EP3406634B1/en active Active
- 2014-01-31 MX MX2015009502A patent/MX360746B/es active IP Right Grant
- 2014-01-31 SG SG10201706226QA patent/SG10201706226QA/en unknown
- 2014-01-31 WO PCT/US2014/014175 patent/WO2014121087A1/en not_active Ceased
- 2014-01-31 KR KR1020157021205A patent/KR102229732B1/ko active Active
- 2014-01-31 FI FIEP18179622.8T patent/FI3406634T3/fi active
- 2014-01-31 HU HUE18179622A patent/HUE067391T2/hu unknown
- 2014-01-31 PL PL14706169T patent/PL2951207T3/pl unknown
-
2015
- 2015-06-29 IL IL239688A patent/IL239688B/en unknown
- 2015-06-29 ZA ZA2015/04697A patent/ZA201504697B/en unknown
- 2015-07-23 MX MX2018013738A patent/MX2018013738A/es unknown
-
2016
- 2016-05-05 US US15/147,791 patent/US10106610B2/en active Active
-
2018
- 2018-09-12 US US16/128,907 patent/US10988537B2/en active Active
- 2018-10-15 JP JP2018193951A patent/JP6687702B2/ja active Active
-
2019
- 2019-02-05 AU AU2019200764A patent/AU2019200764B2/en active Active
-
2020
- 2020-04-01 JP JP2020065490A patent/JP6895558B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2982904T3 (es) | Anticuerpos que comprenden dominios constantes quiméricos | |
| EP3277725B1 (en) | Heavy chain constant regions with reduced binding to fc gamma receptors | |
| JP6805130B2 (ja) | Ｃｄ１２３結合剤及びその使用 | |
| JP6604851B2 (ja) | 不活性フォーマット | |
| CN117098781A (zh) | 靶向cd22和cd79b的抗体 | |
| US12509514B2 (en) | Antibodies comprising chimeric constant domains | |
| HK40114003A (en) | Antibodies comprising chimeric constant domains | |
| HK40000574B (en) | Antibodies comprising chimeric constant domains | |
| HK40000574A (en) | Antibodies comprising chimeric constant domains | |
| BR112015017778B1 (pt) | Anticorpos que compreendem domínios constantes quiméricos | |
| HK1217955B (en) | Antibodies comprising chimeric constant domains | |
| HK1250039B (en) | Heavy chain constant regions with reduced binding to fc gamma receptors |